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ABSTRACT
The goal of the present study was to determine whether insulin-like growth 
factor-1 receptor (IGF-1R) antibodies, conjugated with bright fluorophores, could 
enable visualization of pancreatic cancer in orthotopic nude mouse models. IGF-1R 
antibody (clone 24-31) was conjugated with 550 nm or 650 nm fluorophores. Western 
blotting confirmed the expression of IGF-1R in Panc-1, BxPC3, and MIAPaCa-2 
human pancreatic cancer cell lines. Labeling with fluorophore-conjugated IGF-1R 
antibody demonstrated fluorescent foci on the membrane of the pancreatic cancer 
cells. Subcutaneous Panc-1, BxPC-3, and MIA PaCa-2 tumors became fluorescent 
after intravenous administration of fluorescent IGF-1R antibodies. Orthotopically-
transplanted BxPC-3 tumors became fluorescent with the conjugated IGF-1R 
antibodies, and were easily visible with intravital imaging. Gross and microscopic 
ex vivo imaging of resected pancreatic tumor and normal pancreas confirmed that 
fluorescence indeed came from the membrane of cancer cells, and it was stronger from 
the tumor than the normal tissue. The present study demonstrates that fluorophore-
conjugated IGF-1R antibodies can visualize pancreatic cancer and it can be used 
with various imaging devices such as endoscopy and laparoscopy for diagnosis and 
fluorescence-guided surgery.
INTRODUCTION
For pancreatic cancer, CA19-9 is the only biomarker 
being used in the clinic despite many needs for others 
[1-3]. Several cell surface biomarkers for molecular 
imaging have been reported in pancreatic cancer [4-6]. 
We previously demonstrated that CEA, CA19-9, and 
MUC1 could be targeted in pancreatic cancer with specific 
fluorescent antibodies, enabling imaging in orthotopic 
mouse models [7-9].
Type I insulin-like growth factor receptor (IGF-1R) is 
a potential diagnostic and therapeutic biomarker of several 
cancers [10]. It is a transmembrane tyrosine kinase receptor 
comprising two α and two β chains. IGF-1R is the major 
receptor for IGF-I and IGF-II, and importantly expressed 
in 97.6% of pancreatic cancers [11]. There is also a report 
that the expression of IGF-1R in pancreatic cancer is higher 
than in normal pancreas [12]. IGF-1R plays important roles 
in cell proliferation, apoptosis, angiogenesis, and tumor 
invasion [13-15]. In addition, a few studies have shown 
fluorescence imaging using IGF-1R targeting on tumors 
is possible, and its potential clinical usefulness has been 
discussed [16]. In the present study, we demonstrate that 
fluorescent anti-IGF-1R antibodies target pancreatic cancer 
in orthotopic mouse models enabling non-invasive imaging 
and high resolution intra-vital imaging of the tumor.
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RESULTS
Expression of IGF-1R in pancreatic cancer cells 
in vitro
Western blotting showed Panc-1, BxPC-3, and 
MIA PaCa-2 pancreatic cancer cell lines expressed IGF-
1R (Figure 1A). After incubation with the fluorophore-
conjugated IGF-1R antibody, without permeation, multiple 
fluorescent foci were visualized on the membrane of Panc-
1 and BxPC-3 cells under fluorescence microscopy (Figure 
1B) confirming the expression of IGF-1R on cancer cells.
Targeting subcutaneous pancreatic tumors in 
nude mice with fluorescent IGF-1R antibodies
When Panc-1, BxPC-3, and MIA PaCa-2 
subcutaneous tumors reached approximately 10 mm in 
diameter, a single 30 μg dose of DyLight 650-conjugated 
anti-IGF-1R (clone 24-31) in 150 μl PBS was injected 
via the tail vein. The mice were imaged by both bright-
field and fluorescence illumination using the variable 
magnification OV100 48 hours after the injection. All the 
subcutaneous tumors had stronger fluorescence compared 
to background (Figure 2).
Targeting orthotopic pancreatic tumors in nude 
mice with fluorescent IGF-1R antibodies
Mice with BxPC-3 tumors, orthotopically-implanted 
in the tail of the pancreas, were injected with DyLight 
650-conjugated anti-IGF-1R (clone 24-31) antibody. 
A single 30 μg dose in 150 μl PBS was injected via the 
tail vein 14 days after tumor implantation. After opening 
the abdomen, the OV100 detected the bright tumor 
fluorescence (Figure 3). Minimal fluorescence was also 
observed at the skin, bladder, and intestinal contents which 
had lower intensity than the tumor.
Ex-vivo microscopic imaging of orthotopic 
pancreatic tumors with fluorescent IGF-1R 
antibodies
Mice with BxPC-3 tumors, orthotopically-implanted 
in the tail of the pancreas were injected with a single 10 
μg dose of DyLight 650-conjugated anti-IGF-1R (clone 
24-31) in 150 μl PBS dose via the tail vein 14 days after 
tumor implantation. After opening the abdomen, the 
tumor, normal pancreas and spleen were resected as a 
block. They were observed under the IV-100 scanning 
laser microscope with a microprobe objective lens (1.3 
mm diameter) (Figure 4A). A strong fluorescence signal on 
the surface of cancer cells was detected at high resolution 
with only minimal fluorescence in the interstitium of 
the normal pancreas (Figure 4B). Hematoxylin & eosin 
staining of tissue samples and immuno fluorescence 
staining confirmed the expression of IGF-1R in the 
pancreatic cancer tissues (Figure 4C).
DISCUSSION
In the present study, we used a microprobe objective 
lens for ex vivo imaging, which had x20 magnification 
power and a diameter of 1.3 mm. It resembles a confocal 
laser endomicroscope which has a diameter of 0.8 ~ 
2.8mm [17]. Our results suggest microscopic fluorescence 
imaging using such a device could allow detection of IGF-
1R in vivo without tissue sampling.
Recent progress in fluorescence imaging and 
devices has allowed finer visualization of not only 
hollow organs such as the esophagus, stomach and 
Figure 1: Characterization of pancreatic cancer cell lines. A. Western blot analysis shows pro-IGF-1R and IGF-1Rα expression 
at 200 and 130 kDa in pancreatic cancer cell lines, respectively (Panc-1, BxPC-3, MIA PaCa-2). B. Labeling of live Panc-1 and BxPC-3 
cells with 550 nm fluorophore-conjugated antibodies shows multiple fluorescent foci on the cell membrane. Merged images were created 
with corresponding DIC (differential interference contrast) images (x60 water immersion objective with the FV1000 confocal microscope, 
using the 559 nm laser).
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colon, but also intra-abdominal solid organs such as 
the liver, spleen, and pancreas [18-21]. Fluorescence 
imaging for pancreatic cancer can be especially useful 
since it can reduce the time and errors associated with 
tissue biopsy. Since IGF-1R is very frequently expressed 
in pancreatic cancer, and its expression is stronger than 
in the normal pancreas [11, 12], detecting IGF-1R can be 
used for diagnosis purposes. We have previously shown 
Figure 2: Imaging of 650 nm fluorophore-conjugated IGF-1R antibody targeted subcutaneous pancreatic tumors in 
vivo. The mouse is imaged under both white light and fluorescence illumination with the OV100. The intensity of fluorescence from the 
Panc-1, BxPC-3, MIA PaCa-2 subcutaneous tumors are stronger than background.
Figure 3: Imaging of fluorophore-conjugated IGF-1R antibody targeted orthotopically-transplanted BxPC3 pancreatic 
tumors in vivo and ex vivo. Fluorescence from orthotopically-transplanted pancreatic tumors in the tail of the pancreas was detected in 
vivo with the OV100 after abdominal laparotomy. Weak fluorescence was also detected from the skin and, bladder and intestinal contents, 
but at much lower intensity than the tumor. Also, fluorescence from the resected tumor was detected at high resolution with the IV100, but 
not from the normal pancreas. White arrows indicate pancreatic tumor.
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that fluorescence guided surgery (FGS) can increase 
survival or effect cures in pancreatic cancer mouse 
models [22]. Targeting IFG-1R in pancreatic cancer with 
fluorophore conjugated antibodies may also be useful for 
fluorescence-guided surgery.
IGF-1R fluorescent antibody binding to pancreatic 
cancer cells and tumors is specific, as shown by Western 
blotting of IGF-1R binding to the cancer cell membranes 
(Figure 1) by the much greater antibody-derived 
fluorescence, compared to non-specific autofluorescence, 
and in orthotopic as well as subcutaneous tumors seen 
by both microscopic as well as endoscopic-like imaging 
devices, and by histological experiments which showed that 
the antibody specifically binds to tumor tissue (Figure 4).
The present study is a major advance over previous 
studies [16, 23] on binding of IDG-1R fluorescent 
antibodies to pancreatic cancer as our model is orthotopic 
and therefore clinically relevant, including the fact that an 
endoscope-like device can detect the fluorescent IGF-1R 
antibody bound to tumor tissue.
With regard to the choice of fluorophore to 
conjugate to IGF-1R antibodies, we used DyLight 650 
and 550 dyes because our previous studies demonstrated 
that these longer-wavelength dyes had increased depth 
of penetration and ability to detect the smallest tumor 
deposits and provided the highest tumor-background 
ratios (TBRs), resistance to hemoglobin quenching, and 
specificity compared to shorter wavelength dyes [24]. 
Other fluorophores may be useful in terms of colors and 
chemistry as outlined by Kobayashi et al [25, 26].
The tumor-targeting technology described in 
the present report can be used along with previously 
developed tumor-targeting strategies [27-32].
MATERIALS AND METHODS
Pancreatic cancer cell lines
The human pancreatic cancer cell lines BxPC-3 
[33] and Panc-1 [34] MIA PaCa-2 were maintained in 
RPMI 1640 medium and DMEM supplemented with 10% 
fetal bovine serum (Hyclone, Logan, UT), and penicillin/
streptomycin (Gibco-BRL, Carlsbad, CA). All cells were 
cultured at 37° C in a 5% CO2 incubator.
Figure 4: Ex-vivo microscopic imaging of an orthotopic pancreatic tumor labeled with fluorescent anti-IGF-1R 
antibody. A. Microprobe lens (x20) used with the IV-100. B. Ex vivo imaging done with the IV-100 visualized fluorescence from the 
surface of BxPC-3 cancer cells in the orthotopic tumor with anti-IGF-1R conjugated to a 650 nm DyLight dye. C. H & E and fluorescence 
staining of a tissue sample (x200) confirm the specific expression of IGF-1R on the surface of the pancreatic cancer cells.
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Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in the study. Mice 
were kept in a barrier facility under HEPA filtration and 
fed with an autoclaved laboratory rodent diet. All mouse 
surgical procedures and imaging were performed after 
anesthetized by intramuscular injection of 50% ketamine, 
38% xylazine, and 12% acepromazine maleate (0.02 
ml). Animals received buprenorphine (0.10 mg/kg ip) 
immediately prior to surgery and once a day over the next 
3 days. The maximum tumor size allowed to grow was 
2 cm. The condition of the animals was monitored every 
day. CO2 inhalation was used for euthanasia. To ensure 
death following CO2 asphyxiation, cervical dislocation 
was performed. All animal studies were approved by 
AntiCancer, Inc.’s Institutional Animal Care and Use 
Committee (IACUC) in accordance with the principals 
and procedures outlined in the National Institute of Health 
Guide for the Care and Use of Animals under Assurance 
Number A3873-1.
Antibody-dye conjugation
Mouse monoclonal antibodies to IGF-1R (clone 
24-31; Thermo Scientific, Rockford, IL, USA) were 
conjugated with DyLight 650 or 550 dyes (Thermo 
Scientific, Rockford, IL, USA) per manufacturer 
specifications, ensuring a minimum of at least 4:1 dye: 
protein ratio. Protein: dye concentrations were confirmed 
using a NanoDrop Spectrophotometer (Thermo Fisher 
Scientific, Waltham, Massachusetts) [24].
Western blotting
Cell lysates were extracted in lysis buffer 
containing 70 mM β-glycerophosphate, 0.6 mM sodium 
orthovanadate, 2 mM MgCl2, 1 mM ethylene glycol 
tetraacetic acid, 1 mM DTT (Invitrogen, Grand Island, NY, 
USA), 0.5% Triton-X100, 0.2 mM phenylmethylsulfonyl 
fluoride, and 1% protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA). Lysates were separated by 
sodium dodecylsulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to polyvinylidene fluoride 
membranes (Millipore, Billerica, MA, USA). The 
membranes were blocked in 5% (w/v) non-fat dry milk 
and probed with anti-IGF-1R (SC-712; Santa Cruz, Dallas, 
TX, USA). The immunoreactive proteins were visualized 
using the SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific).
Labeling of live cells in vitro using fluorescent 
IGF-1R antibodies
Panc-1 and BxPC-3 cells (2 x 105) were cultured 
overnight. Anti-IGF-1R (clone 24-31) conjugated with 
DyLight 550 dye was diluted to 4 μg/ml in phosphate-
buffered saline (PBS, Corning Cellgro, Manassas, VA). 
The culture medium from the cells was aspirated and the 
diluted antibody was added to the live cells. Cells were 
incubated with antibody for 1 hour at room temperature. 
The cells were washed gently 2 times with PBS after the 
antibody was aspirated. The cells were observed under an 
FV1000 confocal microscope (Olympus, Tokyo, Japan) 
with white light and 559 nm laser [35].
Immunohistochemistry
Anti-IGF-1R (clone 24-31) conjugated with 
DyLight 650 was used for staining tumor sections on 
slides. The slides were incubated with 10% normal donkey 
serum for 1 hour at room temperature, and incubated with 
the conjugated antibody at room temperature for 1 hour at 
a dilution of 1:100. Tissues were dried and observed with 
an IV-100 scanning laser microscope (Olympus, Tokyo, 
Japan) with a 633 nm laser [36]. Alternate slides from the 
same frozen tumor tissue were stained with hematoxylin 
and eosin and observed under light microscopy.
Subcutaneous and orthotopic tumor mouse 
models
To make subcutaneously-transplanted pancreatic 
tumor models, Panc-1, BxPC-3, and MIA PaCa-2 
human pancreatic cancer cells (2 × 106) were injected 
subcutaneously into the flanks of nude mice. When the 
subcutaneous tumors grew between 10 and 20 mm 
in diameter, imaging of the subcutaneous tumor was 
performed. To make orthotopic-tumor mouse models, 
subcutaneous tumors were harvested and divided into 
small fragments which were implanted onto the tail of 
the pancreas using 8-0 nylon sutures in nude mice, as 
previously described [37-40].
Whole body and intra-vital imaging
In both subcutaneous and orthotopic tumor models, 
the mice were injected with the fluorescent antibody in 
the tail vein. After 48 hours, whole body non-invasive and 
intra-vital imaging of the subcutaneous and orthotopic 
tumors was performed using the OV100 Small Animal 
Imaging System (Olympus, Tokyo, Japan) [41]. The 
optimal dose for animal studies was decided by the amount 
of the conjugated antibody which produced images with 
the best TBR in the subcutaneous-tumor model.
Intravital laser scanning microscope
The IV-100 (Olympus) and the conjugated antibody 
were used to obtain microscopic fluorescence images 
of pancreatic tumors and the normal pancreas in the 
orthotopic mouse model. The IV-100 operates with four 
lasers (488, 561, 633, and 748 nm) for excitation; three 
of which can be used simultaneously for imaging. Its 
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microprobe lens has an external diameter of 1.3 mm and 
delivers high resolution images in the visible and near-
infrared spectrum. Due to its small size, it can be used 
to image abdominal organs through a small incision [42].
Image analysis
All images were analyzed using Image-J (National 
Institutes of Health, Bethesda, Maryland) before the 
process of images and compared. Image process was done 
with Adobe Photoshop CS3 (Adobe Systems Inc., San 
Jose, California).
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